EP3858388B1 - T-zellen mit chimärem antigenrezeptor (car) als therapeutische eingriffe bei gvhd - Google Patents
T-zellen mit chimärem antigenrezeptor (car) als therapeutische eingriffe bei gvhd Download PDFInfo
- Publication number
- EP3858388B1 EP3858388B1 EP21154942.3A EP21154942A EP3858388B1 EP 3858388 B1 EP3858388 B1 EP 3858388B1 EP 21154942 A EP21154942 A EP 21154942A EP 3858388 B1 EP3858388 B1 EP 3858388B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cells
- car
- human
- composition
- human patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title claims description 41
- 210000001744 T-lymphocyte Anatomy 0.000 title description 60
- 230000001225 therapeutic effect Effects 0.000 title description 6
- 210000004027 cell Anatomy 0.000 claims description 88
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 40
- 210000003289 regulatory T cell Anatomy 0.000 claims description 31
- 239000000427 antigen Substances 0.000 claims description 29
- 108091007433 antigens Proteins 0.000 claims description 29
- 102000036639 antigens Human genes 0.000 claims description 29
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 23
- 208000024908 graft versus host disease Diseases 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 10
- 150000007523 nucleic acids Chemical group 0.000 claims description 7
- 230000037396 body weight Effects 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 210000003720 plasmablast Anatomy 0.000 claims description 5
- 210000004180 plasmocyte Anatomy 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 230000000735 allogeneic effect Effects 0.000 claims description 3
- 210000003071 memory t lymphocyte Anatomy 0.000 claims description 3
- 241000699670 Mus sp. Species 0.000 description 52
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 22
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 22
- 101100383038 Homo sapiens CD19 gene Proteins 0.000 description 22
- 241000699666 Mus <mouse, genus> Species 0.000 description 22
- 101100368976 Arabidopsis thaliana TBL12 gene Proteins 0.000 description 21
- 101100540999 Oryza sativa subsp. japonica XOAT1 gene Proteins 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 201000010099 disease Diseases 0.000 description 17
- 239000011324 bead Substances 0.000 description 16
- 230000001684 chronic effect Effects 0.000 description 16
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 13
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 13
- 239000005090 green fluorescent protein Substances 0.000 description 12
- 210000004698 lymphocyte Anatomy 0.000 description 11
- 238000010361 transduction Methods 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 10
- 208000023275 Autoimmune disease Diseases 0.000 description 9
- 210000005259 peripheral blood Anatomy 0.000 description 9
- 239000011886 peripheral blood Substances 0.000 description 9
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 8
- 230000026683 transduction Effects 0.000 description 8
- 230000001363 autoimmune Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 5
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 5
- 230000009089 cytolysis Effects 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 4
- 108700031361 Brachyury Proteins 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 201000001981 dermatomyositis Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 102100027207 CD27 antigen Human genes 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 description 2
- 206010042953 Systemic sclerosis Diseases 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 108700042075 T-Cell Receptor Genes Proteins 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002825 functional assay Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 208000005987 polymyositis Diseases 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108010056030 retronectin Proteins 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 230000000153 supplemental effect Effects 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 206010055128 Autoimmune neutropenia Diseases 0.000 description 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 108010005327 CD19-specific chimeric antigen receptor Proteins 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 208000011038 Cold agglutinin disease Diseases 0.000 description 1
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000004332 Evans syndrome Diseases 0.000 description 1
- 201000003542 Factor VIII deficiency Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 description 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000009567 Neonatal Alloimmune Thrombocytopenia Diseases 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 208000034943 Primary Sjögren syndrome Diseases 0.000 description 1
- 208000003670 Pure Red-Cell Aplasia Diseases 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102100029198 SLAM family member 7 Human genes 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 102100038081 Signal transducer CD24 Human genes 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 102100035721 Syndecan-1 Human genes 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 208000005707 acquired angioedema Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 206010061811 demyelinating polyneuropathy Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 208000001031 fetal erythroblastosis Diseases 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 201000008269 immune-complex glomerulonephritis Diseases 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 238000009613 pulmonary function test Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000002568 urticarial effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464404—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0387—Animal model for diseases of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10041—Use of virus, viral particle or viral elements as a vector
- C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Definitions
- treatment refers to reversing, alleviating, or inhibiting the progress of an autoimmune or alloimmune disease, or one or more symptoms associated with such an autoimmune or alloimmune disease. It would be understood that the particular therapeutic endpoint(s) that determines whether or not treatment has been achieved (e.g., whether or not a patient has been treated) will depend upon whether the patient suffers from an autoimmune disease or an alloimmune disease as well as the particular type of autoimmune or alloimmune disease.
- a 24-well tissue culture plate was coated with 100 ⁇ g/mL RetroNectin in PBS. Samples were incubated at room temperature for 3 hr OR overnight at 4°C.
- T cell counts were obtained daily or every other day to maintain a T cell concentration of 1-2 x 10 ⁇ 6 cells/mL for optimal expansion and viability. 1-2 wells per condition were reserved to use for counting and not for eventual ACT.
- transduction efficiency of T cells was analyzed by FACS. Cells were harvested as appropriate for functional assays.
- transduction efficiency of T cells was analyzed by FACS. Optimal efficiency was generally observed between day 6 and day 7. Cells were harvested for functional assays, typically on the day of adoptive transfer.
- TBL12.huCD19 The human CD19 gene, along with reporter genes encoding green fluorescent protein (GFP) and luciferase, were introduced into a mouse B cell tumor called TBL12. This derivative was designated TBL12.huCD19. Both the parental TBL12 and the derivative TBL12.huCD19 lines express mouse CD19, but only the derivative line, TBL12.huCD19, expresses human CD19 and GFP. Both of these proteins are detectable by flow cytometry.
- GFP green fluorescent protein
- the anti-human CAR T cells specifically kill human CD19-bearing tumor targets in vitro.
- Anti-human CD19 CAR T cells (0.3 x 10 ⁇ 6), or control T cells transduced with a retrovirus encoding the reporter protein GFP (0.3 x 10 ⁇ 6), were injected intravenously into huCD19TG +/- mice. After four days, mice were euthanized and their spleens removed and frozen in optimal cutting temperature tissue medium. Thin (10 ⁇ m) sections were cut on a cryostat, fixed, and stained with fluorophore-conjugated antibodies specific for endogenous B cells or the adoptively transferred T cells. Tissue images were captured by confocal microscopy at 20X magnification.
- Figure 4A shows massive accumulation of CAR T cells (green) in the spleen of a huCD19TG +/- mouse, and no detectable endogenous B cells (red).
- Figure 4B shows the spleen from a control huCD19TG +/- mouse injected with T cells treated identically to the CAR T cells except the retrovirus encoded GFP, not the anti-human CD19 CAR. Endogenous B cells (red) are plentiful and the infiltrating T cells (green) are detectable but have not expanded to the extent seen in Figure 4A .
- the experimental results shown in Figures 4A and 4B demonstrate that CAR T cells engineered and expanded ex vivo kill human CD19 + B cells when transferred into huCD19TG +/- mice.
- the huCD19TG +/- model is suitable to assess on-target/off-tumor toxicity.
- Tregs were purified from LN + SP of 115 wild type (WT) B6 mice using EasySep CD4 negative selection and CD25 positive selection. Analysis showed that the resulting product contained 99.9% CD4+ CD25+. Once purified, Tregs were activated for 4 days using plate-bound anti-CD3+ (2 ⁇ g) and CD28+ antibodies (4 ⁇ g).
- Tregs were then transduced with either CAR hCD19-EGFR or Control RV-EGFR using routine methods. On day 5 post-transduction efficiency was low, so cells were transduced a second time using the same methods. On day 7 post-transduction, transduction efficiency was about 30% for both CAR hCD19 Treg cells and control Treg cells. At day 7 post-transduction, the purity was >93% for both groups, and the yield was 26.75 million CAR hCD19 Treg cells and 22.5 million control Treg cells.
- Figure 5 shows pulmonary function after 60 days;
- Figure 5A shows resistance of mice without or with chronic GVHD, and chronic GVHD mice treated on day 28 with CAR-T cells or GFP-T cells. High resistance indicative of chronic GVHD was reversed by CAR-T cells but not GFP-T cells;
- Figure 5B shows elastance of transplantation mice without or with chronic GVHD, and chronic GVHD mice treated on day 28 with CAR-T cells or GFP-T cells. High elastance indicative of chronic GVHD was reversed by CAR-T cells but not GFP-T cells;
- Figure 5C shows low compliance of transplantation mice without or with chronic GVHD, and chronic GVHD mice treated on day 28 with CAR-T cells or GFP T-cells. Low compliance indicative of chronic GVHD was reversed by CAR-T cells but not GFP-T cells.
- Figure 6 shows that hCD19+ cells persist in recipient mice at 4 days post-transplantation (from CD4- lymphocytes).
- Figure 7 shows that the addition of CAR CD19 Treg cells significantly improved survival of transplanted mice compared to mice transplanted with only bone marrow and T cells or mice transplanted with bone marrow and control Treg cells.
- Figure 8 shows that the weight loss of transplanted mice were similar, irrespective of whether T cells and/or CAR CD 19 Treg cells were delivered to the mice.
- Figure 9 shows that mice transplanted with bone marrow, T cells and CAR CD 19 Treg cells exhibited a better clinical score than mice transplanted with bone marrow alone and a clinical score similar to mice transplanted with bone marrow and T cells or bone marrow, T cells and control Treg cells.
- CAR-T cells, but not GFP-T cells caused weight loss and clinical findings consistent with a cytokine release syndrome in CD19 heterozygous mice, unexpectedly, neither CAR-T cells nor GFP-T cells adversely affected survival.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (10)
- Eine pharmazeutische Zusammensetzung zur Verwendung bei der Behandlung von Graft-vs-Host-Disease (GVHD) in einem menschlichen Patienten, wobei die pharmazeutische Zusammensetzung eine therapeutisch effektive Menge einer Population von modifizierten humanen regulatorischen T-Zellen (Treg-Zellen) umfasst, wobei die humanen Treg-Zellen modifiziert sind, um eine Nukleinsäuresequenz zu exprimieren, die ein chimäres Antigenrezeptor (CAR) -konstrukt kodiert, wobei das CARkonstrukt eine Antigenbindedomäne umfasst, wobei die Antigenbindedomäne spezifisch ist für CD19.
- Die Zusammensetzung zur Verwendung nach Anspruch 1, wobei die Treg-Zellen autolog in Bezug auf den menschlichen Patienten sind.
- Die Zusammensetzung zur Verwendung nach Anspruch 1, wobei die Treg-Zellen allogen in Bezug auf den menschlichen Patienten sind.
- Die Zusammensetzung zur Verwendung nach einem der vorhergehenden Ansprüche, wobei die modifizierten Treg-Zellen in vivo in dem menschlichen Patienten replizieren.
- Die Zusammensetzung zur Verwendung nach einem der vorhergehenden Ansprüche, wobei die modifizierten Treg-Zellen Memory T-Zellen in dem menschlichen Patienten gegen B-Zellen, Plasmazellen oder Plasmablasten bilden, die einen Liganden exprimieren, der von der Antigenbindedomäne erkannt wird.
- Die Zusammensetzung zur Verwendung nach einem der vorhergehenden Ansprüche, wobei die effektive Menge der Treg-Zellen zwischen etwa 104 und etwa 109 Zellen pro kg Körpergewicht des menschlichen Patienten ist.
- Die Zusammensetzung zur Verwendung nach einem der vorhergehenden Ansprüche, wobei die effektive Menge von Treg-Zellen zwischen etwa 105 und etwa 106 Zellen pro kg Körpergewicht des menschlichen Patienten ist.
- Die Zusammensetzung zur Verwendung nach einem der vorhergehenden Ansprüche, wobei die Antigenbindedomäne ein Antikörper oder ein Antigen-bindendes Fragment davon ist.
- Die Zusammensetzung zur Verwendung nach Anspruch 8, wobei das Antigen-bindende Fragment ein Fab oder ein scFv ist.
- Die Zusammensetzung zur Verwendung nach einem der vorhergehenden Ansprüche, wobei die modifizierten Treg-Zellen intravenös an den menschlichen Patienten zu verabreichen sind.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562233908P | 2015-09-28 | 2015-09-28 | |
EP16852441.1A EP3355937A4 (de) | 2015-09-28 | 2016-09-28 | T-zellen mit chimärem antigenrezeptor (car) als therapeutische eingriffe bei auto- und allo-immunität |
PCT/US2016/054076 WO2017058850A1 (en) | 2015-09-28 | 2016-09-28 | Chimeric antigen receptor (car) t cells as therapeutic interventions for auto- and allo-immunity |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16852441.1A Division EP3355937A4 (de) | 2015-09-28 | 2016-09-28 | T-zellen mit chimärem antigenrezeptor (car) als therapeutische eingriffe bei auto- und allo-immunität |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3858388A1 EP3858388A1 (de) | 2021-08-04 |
EP3858388B1 true EP3858388B1 (de) | 2024-07-03 |
Family
ID=58427315
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16852441.1A Withdrawn EP3355937A4 (de) | 2015-09-28 | 2016-09-28 | T-zellen mit chimärem antigenrezeptor (car) als therapeutische eingriffe bei auto- und allo-immunität |
EP21154942.3A Active EP3858388B1 (de) | 2015-09-28 | 2016-09-28 | T-zellen mit chimärem antigenrezeptor (car) als therapeutische eingriffe bei gvhd |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16852441.1A Withdrawn EP3355937A4 (de) | 2015-09-28 | 2016-09-28 | T-zellen mit chimärem antigenrezeptor (car) als therapeutische eingriffe bei auto- und allo-immunität |
Country Status (6)
Country | Link |
---|---|
US (1) | US20180264038A1 (de) |
EP (2) | EP3355937A4 (de) |
JP (2) | JP2018534264A (de) |
CN (1) | CN108348620A (de) |
HK (1) | HK1258726A1 (de) |
WO (1) | WO2017058850A1 (de) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
AU2018367896B2 (en) | 2017-05-12 | 2023-06-01 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
WO2019089858A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
EP3714271A1 (de) * | 2017-11-20 | 2020-09-30 | Julius-Maximilians-Universität Würzburg | Cd19cart-zellen eliminieren myelomzellen, die sehr niedrige cd19-spiegel exprimieren. |
KR20200144093A (ko) | 2018-02-17 | 2020-12-28 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 막 단백질 전달을 위한 조성물 및 방법 |
BR112020022879A2 (pt) | 2018-05-11 | 2021-02-23 | Crispr Therapeutics Ag | métodos e composições para tratamento de câncer |
CN109021114B (zh) * | 2018-08-08 | 2020-06-09 | 武汉波睿达生物科技有限公司 | 联合两种单链抗体的双特异性嵌合抗原受体及表达载体 |
JP2022507453A (ja) | 2018-11-14 | 2022-01-18 | フラッグシップ パイオニアリング イノベーションズ ブイ, インコーポレイテッド | T細胞送達のためのフソソーム組成物 |
CN111454358A (zh) * | 2019-01-18 | 2020-07-28 | 四川科伦博泰生物医药股份有限公司 | 一种嵌合抗原受体及其应用 |
US20220249558A1 (en) | 2019-04-30 | 2022-08-11 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
WO2021034684A1 (en) * | 2019-08-16 | 2021-02-25 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Chimeric antigen receptors for treating myeloid malignancies |
CA3152525A1 (en) | 2019-09-03 | 2021-03-11 | Sana Biotechnology, Inc. | Cd24-associated particles and related methods and uses thereof |
US20210254097A1 (en) * | 2019-09-06 | 2021-08-19 | Avectas Limited | Engineering of immune cells for ex vivo cell therapy applications |
US20230293581A1 (en) | 2020-08-13 | 2023-09-21 | Sana Biotechnology, Inc. | Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions |
WO2022146891A2 (en) | 2020-12-31 | 2022-07-07 | Sana Biotechnology, Inc. | Methods and compositions for modulating car-t activity |
AU2022206324A1 (en) | 2021-01-11 | 2023-07-20 | Sana Biotechnology, Inc. | Use of cd8-targeted viral vectors |
WO2022246293A1 (en) | 2021-05-19 | 2022-11-24 | Sana Biotechnology, Inc. | Hypoimmunogenic rhd negative primary t cells |
CA3216346A1 (en) | 2021-05-27 | 2022-12-01 | Edward Rebar | Hypoimmunogenic cells comprising engineered hla-e or hla-g |
WO2022251712A1 (en) | 2021-05-28 | 2022-12-01 | Sana Biotechnology, Inc. | Lipid particles containing a truncated baboon endogenous retrovirus (baev) envelope glycoprotein and related methods and uses |
EP4370544A2 (de) | 2021-07-14 | 2024-05-22 | Sana Biotechnology, Inc. | Veränderte expression von y-chromosom-gebundenen antigenen in hypoimmunogenen zellen |
CN113663061A (zh) * | 2021-08-04 | 2021-11-19 | 上海优卡迪生物医药科技有限公司 | Cd38在制备car-t药物中的应用 |
TW202321457A (zh) | 2021-08-04 | 2023-06-01 | 美商薩那生物科技公司 | 靶向cd4之病毒載體之用途 |
EP4384193A2 (de) | 2021-08-11 | 2024-06-19 | Sana Biotechnology, Inc. | Genetisch modifizierte zellen für allogene zelltherapie zur reduzierung von durch instant-blut vermittelten entzündungsreaktionen |
KR20240073006A (ko) | 2021-08-11 | 2024-05-24 | 사나 바이오테크놀로지, 인크. | 동종이계 세포 요법을 위한 유전자 변형된 1차 세포 |
KR20240053673A (ko) | 2021-08-11 | 2024-04-24 | 사나 바이오테크놀로지, 인크. | 저면역원성 세포 내 유전자 발현을 변경하기 위한 유도성 시스템 |
AU2022325231A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions |
WO2023019226A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy |
WO2023115041A1 (en) | 2021-12-17 | 2023-06-22 | Sana Biotechnology, Inc. | Modified paramyxoviridae attachment glycoproteins |
TW202342498A (zh) | 2021-12-17 | 2023-11-01 | 美商薩那生物科技公司 | 經修飾副黏液病毒科融合醣蛋白 |
WO2023122337A1 (en) | 2021-12-23 | 2023-06-29 | Sana Biotechnology, Inc. | Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods |
WO2023150518A1 (en) | 2022-02-01 | 2023-08-10 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
WO2023154578A1 (en) | 2022-02-14 | 2023-08-17 | Sana Biotechnology, Inc. | Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells |
WO2023158836A1 (en) | 2022-02-17 | 2023-08-24 | Sana Biotechnology, Inc. | Engineered cd47 proteins and uses thereof |
WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
WO2023240042A1 (en) | 2022-06-06 | 2023-12-14 | Caribou Biosciences, Inc. | Treatment of autoimmune diseases with engineered immune cells |
WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
WO2024097311A2 (en) | 2022-11-02 | 2024-05-10 | Sana Biotechnology, Inc. | Hypoimmunogenic mail cells, methods of making and methods of using same |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5573924A (en) | 1992-09-08 | 1996-11-12 | Immunex Corporation | CD27 ligand |
US7744877B2 (en) | 1992-11-13 | 2010-06-29 | Biogen Idec Inc. | Expression and use of anti-CD20 Antibodies |
US5484892A (en) | 1993-05-21 | 1996-01-16 | Dana-Farber Cancer Institute, Inc. | Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells |
US6106834A (en) | 1993-06-02 | 2000-08-22 | Research Corporation Technologies, Inc. | Use of anti-CD45 leukocyte antigen antibodies for immunomodulation |
CN102007147B (zh) | 2008-06-30 | 2014-11-05 | 协和发酵麒麟株式会社 | 抗cd27抗体 |
DK3006459T3 (da) | 2008-08-26 | 2021-12-06 | Hope City | Fremgangsmåde og sammensætninger til forbedring af t-cellers antitumoreffektorfunktion |
HUE029619T4 (en) | 2009-03-10 | 2017-07-28 | Biogen Ma Inc | Anti-bcma antibodies |
US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
WO2011060218A1 (en) * | 2009-11-13 | 2011-05-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modulated programmed death ligand-1 |
US20120141505A1 (en) * | 2010-11-01 | 2012-06-07 | Fatih M. Uckun | Cd19-ligand and use |
ES2700966T3 (es) | 2010-12-09 | 2019-02-20 | Univ Pennsylvania | Utilización de linfocitos T modificados con receptores de antígeno quiméricos para tratar el cáncer |
JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
EA034644B1 (ru) * | 2012-07-13 | 2020-03-02 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Применение cart19 для истощения нормальных b-клеток для индукции толерантности |
TWI654206B (zh) * | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗-cd19嵌合抗原受體治療癌症 |
-
2016
- 2016-09-28 EP EP16852441.1A patent/EP3355937A4/de not_active Withdrawn
- 2016-09-28 US US15/764,187 patent/US20180264038A1/en active Pending
- 2016-09-28 WO PCT/US2016/054076 patent/WO2017058850A1/en active Application Filing
- 2016-09-28 CN CN201680062620.5A patent/CN108348620A/zh active Pending
- 2016-09-28 JP JP2018516558A patent/JP2018534264A/ja active Pending
- 2016-09-28 EP EP21154942.3A patent/EP3858388B1/de active Active
-
2019
- 2019-01-22 HK HK19101127.3A patent/HK1258726A1/zh unknown
-
2021
- 2021-10-29 JP JP2021177696A patent/JP2022023194A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3858388A1 (de) | 2021-08-04 |
EP3355937A4 (de) | 2019-04-17 |
WO2017058850A1 (en) | 2017-04-06 |
EP3355937A1 (de) | 2018-08-08 |
JP2022023194A (ja) | 2022-02-07 |
JP2018534264A (ja) | 2018-11-22 |
US20180264038A1 (en) | 2018-09-20 |
HK1258726A1 (zh) | 2019-11-15 |
CN108348620A (zh) | 2018-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3858388B1 (de) | T-zellen mit chimärem antigenrezeptor (car) als therapeutische eingriffe bei gvhd | |
US10906984B2 (en) | CAR expression vector and CAR-expressing T cells | |
JP2023015098A (ja) | 養子細胞療法において投薬するための方法および組成物 | |
US20220025001A1 (en) | Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof | |
JP2023029373A (ja) | キメラ抗体受容体(CARs)の組成物およびその使用方法 | |
EP3833682B1 (de) | Suizidmodulzusammensetzungen und verfahren | |
US20230183313A1 (en) | Isolated chimeric antigen receptor, modified t cell comprising same and use thereof | |
US20240139248A1 (en) | Immunocompetent cell that expresses a cell surface molecule specifically recognizing human mesothelin, il-7 and ccl19 | |
US20220008474A1 (en) | Engineered regulatory t cells | |
WO2018068257A1 (zh) | 通用型car-t细胞及其制备方法和用途 | |
KR20220003586A (ko) | Cd19를 표적화하는 유전공학적으로 조작된 t 세포를 사용한 b 세포 악성종양의 동종이계 세포 요법 | |
WO2020172638A1 (en) | Crispr/cas9 knock-out of cd33 in human hematopoietic stem/ progenitor cells for allogenic transplantation | |
WO2021136415A1 (zh) | 一种纯化ucart细胞的方法与应用 | |
WO2022031597A1 (en) | Methods of producing t regulatory cells, methods of transducing t cells, and uses of the same | |
US20230242666A1 (en) | Methods and Compositions for the Reduction of Chimeric Antigen Receptor Tonic Signaling | |
CN114929867A (zh) | 一种经修饰的免疫效应细胞及其用途 | |
JP2022512789A (ja) | 自殺スイッチを有するt細胞 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED |
|
AC | Divisional application: reference to earlier application |
Ref document number: 3355937 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20220202 |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40057045 Country of ref document: HK |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20230706 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20240130 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: PENNELL, CHRISTOPHER A. Inventor name: FLYNN, RYAN P. Inventor name: BLAZAR, BRUCE R. |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AC | Divisional application: reference to earlier application |
Ref document number: 3355937 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |